表纸
市场调查报告书

肾脏病的药物研发开发平台评估:2018年

Renal Diseases Drug Development Pipeline Review, 2018

出版商 GlobalData 商品编码 766013
出版日期 内容资讯 英文 154 Pages
订单完成后即时交付
价格
Back to Top
肾脏病的药物研发开发平台评估:2018年 Renal Diseases Drug Development Pipeline Review, 2018
出版日期: 2018年12月19日内容资讯: 英文 154 Pages
简介

本报告提供肾脏病的开发平台形势相关概要,开发中的治疗药及治疗药相关开发的主要企业相关之全面性资讯。

第1章 目录

第2章 简介

  • 肾脏病的调查范围
  • 慢性肾脏病 (慢性肾衰竭) :概要
  • 肾纤维化:概要
  • 多发性囊胞肾 (PKD) :概要
  • 末期肾脏病 (末期肾脏病或ESRD) :概要

第3章 治疗药的开发

  • 慢性肾脏病 (慢性肾衰竭)
  • 肾纤维化
  • 多发性囊胞肾 (PKD)
  • 末期肾脏病 (末期肾脏病或ESRD)

第4章 治疗药的评估

  • 慢性肾脏病 (慢性肾衰竭)
  • 肾纤维化
  • 多发性囊胞肾 (PKD)
  • 末期肾脏病 (末期肾脏病或ESRD)

第5章 介入治疗药开发的企业

  • 慢性肾脏病 (慢性肾衰竭)
  • 肾纤维化
  • 多发性囊胞肾 (PKD)
  • 末期肾脏病 (末期肾脏病或ESRD)

第6章 休止计划

  • 慢性肾脏病 (慢性肾衰竭)
  • 肾纤维化
  • 多发性囊胞肾 (PKD)
  • 末期肾脏病 (末期肾脏病或ESRD)

第7章 中止计划

  • 慢性肾脏病 (慢性肾衰竭)
  • 肾纤维化
  • 多发性囊胞肾 (PKD)
  • 末期肾脏病 (末期肾脏病或ESRD)

第8章 产品开发里程碑

  • 慢性肾脏病 (慢性肾衰竭)
  • 肾纤维化
  • 多发性囊胞肾 (PKD)

第9章 附录

目录
Product Code: GBIHC052IDB

Abstract

Summary

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol. There are 58 products in development for this indication.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant. There are 49 products in development for this indication.

Polycystic kidney disease is a disorder in which clusters of cysts develop primarily within the kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in the urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. There are 26 products in development for this indication.

End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant. There are five products in development for this indication.

Molecular targets in development for renal diseases include growth factor receptors, chemokines and kinases. Companies operating in this pipeline space include Angion Biomedica, Prolong Pharmaceuticals and Novartis.

This report "Renal Diseases Drug Development Pipeline Review, 2018"provides an overview of the pipeline landscape for renal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for chronic kidney disease (chronic renal failure), kidney fibrosis, polycystic kidney disease and end-stage kidney disease (end-stage renal disease), and features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents 4

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Introduction 9

  • 2.1 Renal Diseases Report Coverage 9
  • 2.2 Chronic Kidney Disease (Chronic Renal Failure) - Overview 9
  • 2.3 Kidney Fibrosis - Overview 9
  • 2.4 Polycystic Kidney Disease - Overview 9
  • 2.5 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview 9

3 Therapeutics Development 10

  • 3.1 Chronic Kidney Disease (Chronic Renal Failure) 10
  • 3.2 Kidney Fibrosis 19
  • 3.3 Polycystic Kidney Disease 25
  • 3.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 30

4 Therapeutics Assessment 33

  • 4.1 Chronic Kidney Disease (Chronic Renal Failure) 33
  • 4.2 Kidney Fibrosis 40
  • 4.3 Polycystic Kidney Disease 48
  • 4.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 56

5 Companies Involved in Therapeutics Development 61

  • 5.1 Chronic Kidney Disease (Chronic Renal Failure) 61
  • 5.2 Kidney Fibrosis 80
  • 5.3 Polycystic Kidney Disease 93
  • 5.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 99

6 Dormant Projects 102

  • 6.1 Chronic Kidney Disease (Chronic Renal Failure) 102
  • 6.2 Kidney Fibrosis 106
  • 6.3 Polycystic Kidney Disease 107
  • 6.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 109

7 Discontinued Products 110

  • 7.1 Chronic Kidney Disease (Chronic Renal Failure) 110
  • 7.2 Kidney Fibrosis 111
  • 7.3 Polycystic Kidney Disease 111
  • 7.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 111

8 Product Development Milestones 112

  • 8.1 Chronic Kidney Disease (Chronic Renal Failure) 112
  • 8.2 Kidney Fibrosis 127
  • 8.3 Polycystic Kidney Disease 139

9 Appendix 153

  • 9.1 Methodology 153
  • 9.2 Coverage 153
  • 9.3 Secondary Research 153
  • 9.4 Primary Research 153
  • 9.5 Expert Panel Validation 153
  • 9.6 Contact Us 153
  • 9.7 Disclaimer 154

List of Tables

  • Table 1: Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) 10
  • Table 2: Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure) 12
  • Table 3: Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure) 14
  • Table 4: Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure) 15
  • Table 5: Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure) 18
  • Table 6: Number of Products under Development for Kidney Fibrosis 19
  • Table 7: Number of Products under Development by Companies, Kidney Fibrosis 21
  • Table 8: Number of Products under Development by Universities/Institutes, Kidney Fibrosis 22
  • Table 9: Products under Development by Companies, Kidney Fibrosis 23
  • Table 10: Products under Development by Universities/Institutes, Kidney Fibrosis 25
  • Table 11: Number of Products under Development for Polycystic Kidney Disease, Kidney Fibrosis 26
  • Table 12: Number of Products under Development by Companies, Kidney Fibrosis 27
  • Table 13: Number of Products under Development by Universities/Institutes, Kidney Fibrosis 27
  • Table 14: Products under Development by Companies, Kidney Fibrosis 28
  • Table 15: Products under Development by Universities/Institutes, Kidney Fibrosis 29
  • Table 16: Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 30
  • Table 17: Number of Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 31
  • Table 18: Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 32
  • Table 19: Number of Products by Stage and Target, Chronic Kidney Disease (Chronic Renal Failure) 34
  • Table 20: Number of Products by Stage and Mechanism of Action, Chronic Kidney Disease (Chronic Renal Failure) 36
  • Table 21: Number of Products by Stage and Route of Administration, Chronic Kidney Disease (Chronic Renal Failure) 38
  • Table 22: Number of Products by Stage and Molecule Type, Chronic Kidney Disease (Chronic Renal Failure) 40
  • Table 23: Number of Products by Stage and Target, Kidney Fibrosis 42
  • Table 24: Number of Products by Stage and Mechanism of Action, Kidney Fibrosis 45
  • Table 25: Number of Products by Stage and Route of Administration, Kidney Fibrosis 46
  • Table 26: Number of Products by Stage and Molecule Type, Kidney Fibrosis 48
  • Table 27: Number of Products by Stage and Target, Polycystic Kidney Disease 50
  • Table 28: Number of Products by Stage and Mechanism of Action, Polycystic Kidney Disease 52
  • Table 29: Number of Products by Stage and Route of Administration, Polycystic Kidney Disease 54
  • Table 30: Number of Products by Stage and Molecule Type, Polycystic Kidney Disease 55
  • Table 31: Number of Products by Stage and Target, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 57
  • Table 32: Number of Products by Stage and Mechanism of Action, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 58
  • Table 33: Number of Products by Stage and Route of Administration, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 58
  • Table 34: Number of Products by Stage and Molecule Type, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 60
  • Table 35: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Allena Pharmaceuticals Inc 61
  • Table 36: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp 61
  • Table 37: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH 62
  • Table 38: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Arch Biopartners Inc 62
  • Table 39: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc 63
  • Table 40: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc 64
  • Table 41: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG 64
  • Table 42: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH 65
  • Table 43: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd 65
  • Table 44: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd 66
  • Table 45: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Therapeutics Inc 66
  • Table 46: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DiaMedica Therapeutics Inc 67
  • Table 47: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dimerix Bioscience Pty Ltd 67
  • Table 48: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DURECT Corp 68
  • Table 49: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG 69
  • Table 50: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd 69
  • Table 51: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KBP BioSciences Co Ltd 70
  • Table 52: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Klotho Therapeutics Inc 70
  • Table 53: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nash Pharmaceuticals Inc 71
  • Table 54: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG 71
  • Table 55: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health Inc 72
  • Table 56: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Opsidio LLC 72

List of Figures

  • Figure 1: Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) 10
  • Figure 2: Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure) 11
  • Figure 3: Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure) 14
  • Figure 4: Number of Products under Development for Kidney Fibrosis 19
  • Figure 5: Number of Products under Development by Companies, Kidney Fibrosis 20
  • Figure 6: Number of Products under Development for Polycystic Kidney Disease, Kidney Fibrosis 25
  • Figure 7: Number of Products under Development by Companies, Kidney Fibrosis 26
  • Figure 8: Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 30
  • Figure 9: Number of Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 31
  • Figure 10: Number of Products by Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure) 33
  • Figure 11: Number of Products by Stage and Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure) 33
  • Figure 12: Number of Products by Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure) 35
  • Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure) 35
  • Figure 14: Number of Products by Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure) 37
  • Figure 15: Number of Products by Stage and Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure) 38
  • Figure 16: Number of Products by Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure) 39
  • Figure 17: Number of Products by Stage and Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure) 39
  • Figure 18: Number of Products by Top 10 Targets, Kidney Fibrosis 40
  • Figure 19: Number of Products by Stage and Top 10 Targets, Kidney Fibrosis 41
  • Figure 20: Number of Products by Top 10 Mechanism of Actions, Kidney Fibrosis 43
  • Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Fibrosis 44
  • Figure 22: Number of Products by Stage and Routes of Administration, Kidney Fibrosis 46
  • Figure 23: Number of Products by Top 10 Molecule Types, Kidney Fibrosis 47
  • Figure 24: Number of Products by Stage and Top 10 Molecule Types, Kidney Fibrosis 47
  • Figure 25: Number of Products by Top 10 Targets, Polycystic Kidney Disease 48
  • Figure 26: Number of Products by Stage and Top 10 Targets, Polycystic Kidney Disease 49
  • Figure 27: Number of Products by Top 10 Mechanism of Actions, Polycystic Kidney Disease 51
  • Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, Polycystic Kidney Disease 51
  • Figure 29: Number of Products by Routes of Administration, Polycystic Kidney Disease 53
  • Figure 30: Number of Products by Stage and Routes of Administration, Polycystic Kidney Disease 53
  • Figure 31: Number of Products by Molecule Types, Polycystic Kidney Disease 54
  • Figure 32: Number of Products by Stage and Molecule Types, Polycystic Kidney Disease 55
  • Figure 33: Number of Products by Targets, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 56
  • Figure 34: Number of Products by Stage and Targets, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 56
  • Figure 35: Number of Products by Mechanism of Actions, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 57
  • Figure 36: Number of Products by Stage and Mechanism of Actions, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 58
  • Figure 37: Number of Products by Molecule Types, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 59
  • Figure 38: Number of Products by Stage and Molecule Types, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 59
Back to Top